Population Health is Becoming Precision Community Health

 

The concept of population health is evolving rapidly, with a significant shift towards a more targeted approach known as Precision Community Health. Driving this change is the realization that broad health initiatives often overlook the nuanced needs of specific communities, particularly those in rural areas or experiencing generational poverty. With 80% of health outcomes determined by social determinants of health, such as economic stability and access to healthcare, the stakes have never been higher. This transformation begs the question: How can healthcare providers and organizations adapt to meet the unique needs of every community they serve?

This critical inquiry forms the backbone of the latest episode of Healthcare Rethink, A FinThrive Podcast. Host Brian Urban welcomes Jayme Ambrose, CEO of Adobe Population Health, to explore how her organization is leading the charge in this new era of healthcare. The discussion promises to unpack the transition from broad population health strategies to Precision Community Health, with community-focused interventions that address the social determinants impacting health outcomes.

Key points of discussion include:

  • The role of technology and data analysis in identifying and addressing community health needs
  • The importance of human touch in healthcare, exemplified by Adobe Population Health’s approach to care
  • Predictions for the future of community health and the ongoing evolution of healthcare delivery models

Jayme Ambrose brings a rich background to the conversation, with over 30 years of experience as a registered nurse and a deep commitment to community health. Her journey from a psychiatric nurse to the CEO of Adobe Population Health provides a continuous focus on addressing the social needs that impact health outcomes. Ambrose’s work, particularly in rural Medicare populations, has revealed the profound challenges and opportunities in improving community health through targeted interventions.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…